Wedbush Comments on G1 Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Equities researchers at Wedbush boosted their Q2 2024 earnings estimates for G1 Therapeutics in a report released on Wednesday, May 1st. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.18) per share for the quarter, up from their prior forecast of ($0.20). Wedbush currently has a “Outperform” rating and a $5.00 target price on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.59) per share. Wedbush also issued estimates for G1 Therapeutics’ Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.64) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.49) EPS and FY2026 earnings at ($0.37) EPS.

A number of other equities research analysts have also issued reports on GTHX. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of G1 Therapeutics in a report on Wednesday, May 1st. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of G1 Therapeutics in a report on Thursday.

G1 Therapeutics Price Performance

G1 Therapeutics stock opened at $4.49 on Monday. G1 Therapeutics has a 52-week low of $1.08 and a 52-week high of $5.00. The firm has a market capitalization of $234.74 million, a price-to-earnings ratio of -7.24 and a beta of 1.71. The company has a fifty day simple moving average of $3.94 and a 200-day simple moving average of $3.11. The company has a quick ratio of 3.45, a current ratio of 2.94 and a debt-to-equity ratio of 1.34.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. The business had revenue of $14.48 million for the quarter, compared to analysts’ expectations of $15.21 million. During the same period in the previous year, the company earned ($0.53) EPS.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Financial Advocates Investment Management acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth about $39,000. Capstone Investment Advisors LLC acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth about $76,000. Jump Financial LLC acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth about $105,000. Choreo LLC acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth about $107,000. Finally, Creative Financial Designs Inc. ADV lifted its position in shares of G1 Therapeutics by 98.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after purchasing an additional 17,475 shares in the last quarter. Institutional investors and hedge funds own 24.21% of the company’s stock.

Insider Activity at G1 Therapeutics

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the transaction, the insider now owns 169,938 shares of the company’s stock, valued at $785,113.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.23% of the stock is currently owned by insiders.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.